Summary & Overview
HCPCS J1823: Inebilizumab-cdon Injection, 1 mg
HCPCS Level II code J1823 denotes inebilizumab-cdon supplied as an injectable product at a unit dose of 1 mg. This code matters nationally because it identifies administration and billing for a monoclonal antibody biologic that is delivered parenterally in outpatient infusion or injection settings. Accurate coding affects plan coverage determinations, prior authorization workflows, and claims processing for high-cost specialty therapeutics.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of reimbursement benchmarks and typical billing practices for specialty injectable biologics, policy considerations relevant to coverage and medical necessity reviews, and the clinical context for administration in ambulatory infusion sites. Where specific payer policies or fee schedules are absent in the input, the report notes that data are not available.
This briefing equips billing managers, revenue cycle leaders, and policy analysts with a concise reference to the code’s clinical identity, expected sites of service, and the interoperability considerations that affect claims for inebilizumab-cdon.
Billing Code Overview
HCPCS Level II code J1823 represents inebilizumab-cdon supplied as an injection, 1 mg. This medication is administered parenterally and is used for therapeutic clinical indications consistent with inebilizumab-cdon’s labeled uses.
Service type: Injectable biologic therapy
Typical site of service: Outpatient infusion or injection setting, including hospital outpatient departments, physician offices, and infusion centers where parenteral biologic therapies are given.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult diagnosed with neuromyelitis optica spectrum disorder (NMOSD) or another B-cell–mediated autoimmune condition for which inebilizumab is indicated. The patient presents to an outpatient infusion center or specialty clinic for administration of J1823 (inebilizumab-cdon, 1 mg). Prior to infusion, the clinical workflow includes verification of indication, review of prior authorization and payer coverage (for example, Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, Medicare), collection of baseline laboratory studies (CBC with differential, immunoglobulin levels, screening for hepatitis B and tuberculosis as clinically indicated), and assessment for active infection or vaccination status. The first dose is typically given in a monitored infusion setting with vital sign checks before, during, and after infusion; subsequent dosing follows the approved schedule (induction followed by maintenance dosing). Documentation includes the HCPCS code J1823 with appropriate modifier(s), infusion start and stop times, lot number and NDC if required, pre- and post-medication assessments, and any adverse reactions. Post-infusion, the patient is observed per protocol and scheduled for follow-up doses and monitoring visits, including periodic lab tests and neurologic assessments to evaluate therapeutic response and safety.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |